Te Ahumairangi Investment Management Ltd Lowers Stock Position in DaVita Inc. (NYSE:DVA)

Te Ahumairangi Investment Management Ltd lessened its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 12.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 42,170 shares of the company's stock after selling 5,967 shares during the quarter. DaVita makes up 1.3% of Te Ahumairangi Investment Management Ltd's holdings, making the stock its 23rd biggest position. Te Ahumairangi Investment Management Ltd owned about 0.05% of DaVita worth $6,307,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC increased its position in shares of DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company's stock valued at $29,082,000 after buying an additional 154,061 shares in the last quarter. Captrust Financial Advisors increased its holdings in DaVita by 16.6% in the 3rd quarter. Captrust Financial Advisors now owns 3,992 shares of the company's stock worth $654,000 after acquiring an additional 569 shares in the last quarter. Verition Fund Management LLC raised its position in DaVita by 313.6% during the third quarter. Verition Fund Management LLC now owns 9,603 shares of the company's stock worth $1,574,000 after acquiring an additional 7,281 shares during the period. Caisse DE Depot ET Placement DU Quebec purchased a new position in DaVita during the third quarter valued at $1,820,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of DaVita in the third quarter valued at about $454,000. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DVA shares. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. StockNews.com downgraded DaVita from a "buy" rating to a "hold" rating in a research report on Wednesday. Barclays boosted their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $166.33.

DaVita Trading Down 2.8 %

Shares of DVA traded down $4.37 during midday trading on Friday, reaching $149.37. The company had a trading volume of 1,009,511 shares, compared to its average volume of 813,204. DaVita Inc. has a 1-year low of $125.64 and a 1-year high of $179.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The firm has a 50 day simple moving average of $155.75 and a 200-day simple moving average of $157.23. The stock has a market cap of $11.95 billion, a PE ratio of 13.91, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.